Table 1.
Description of study population according to clinical and IgM laboratory definition of measles
Clinical definition | Laboratory IgM definition | ||||
---|---|---|---|---|---|
N = 253 | N = 74 | ||||
n | % | n | % | ||
Gender | Male | 132 | 52 | 34 | 46 |
Age | < 9 months | 23 | 9 | 16 | 22 |
9–23 months | 31 | 12 | 17 | 23 | |
23–59 months | 52 | 21 | 7 | 10 | |
5–9 yrs | 86 | 34 | 12 | 16 | |
10–14 yrs | 38 | 15 | 9 | 12 | |
≥ 15 yrs | 23 | 9 | 13 | 18 | |
Primary cases | 218 | 86 | 63 | 85 | |
Complications* | Yes | 105 | 42 | 47 | 64 |
Mortality† | 8 | 3 | 6 | 8 | |
Measles vaccination‡ | Yes | 116 | 88 | 14 | 58 |
Complications in Clinical definition (N = 251), and in immunoglobulin M (IgM) laboratory definition (N = 74).
Mortality in Clinical definition (N = 246).
Vaccination status was assessed among study population ≥ 9 months presenting vaccination cards. In Clinical definition (N = 132), in IgM laboratory definition (N = 24).